Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

E-ISSN： 1097-0142|124|2|325-334

ISSN： 0008-543x

Source： CANCER, Vol.124, Iss.2, 2018-01, pp. : 325-334

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemtuzumab Ozogamicin (Mylotarg^®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia

Oncology Research and Treatment, Vol. 24, Iss. 4, 2001-09 ,pp. : 356-360

Karger

Access to resources Recommend Favorite

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 401-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Combination of Fludarabine, Cytarabine and Etoposide Is an Active and Well-Tolerated Regimen in Relapsed/Refractory Acute Myeloid Leukemia

Acta Haematologica, Vol. 131, Iss. 4, 2013-11 ,pp. : 202-207

Karger

Access to resources Recommend Favorite

Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia

Acta Haematologica, Vol. 137, Iss. 4, 2017-04 ,pp. : 195-200

Karger

Access to resources Recommend Favorite